EUSA Pharma

EUSA Pharma

Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in the Recordati group

Founded 2006

Hemel Hempstead, United Kingdom 107 employees Venture round Total: $54.20M Biotechnology, Health Care +1

EUSA Pharma, a subsidiary of Recordati Rare Diseases, stands at the forefront of addressing critical gaps in adult and pediatric care for cancer and rare disease patients globally. Founded in 2006, this United Kingdom-based company operates within the Biotechnology, Health Care, and Pharmaceutical sectors.

As part of the overarching Recordati group, known for its staff of over 4,300 dedicated to pharmaceutical innovation, EUSA Pharma benefits from substantial research, development, and marketing expertise. Their mission is encapsulated in the slogan: "Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in the Recordati group".

Investment history includes a notable Venture Round on May 24, 2009, supported by SV Health Investors and Advent Venture Partners. This strategic investment underscores their commitment to uncovering opportunities and aiding those with limited healthcare options, reflecting their core value: "Helping the people with few or no options available is at the heart of everything we do."

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	Undisclosed	2	SV Health Investors, Advent Venture Partners	24 May 2009
Venture Round	Undisclosed	-		01 Jan 2009
Venture Round	$9.10M	6	OrbiMed, First Eagle Investment Management +4	28 Jun 2007
Venture Round	Undisclosed	1	Essex Woodlands Healthcare Partners	07 Mar 2007
Venture Round	$18.60M	10	OrbiMed, Merlin Biomed +8	07 Nov 2006
Venture Round	$12.53M	5	Perceptive Advisors, Highbridge Capital Management +3	13 Dec 2005
Venture Round	$13.97M	2	OrbiMed, ProQuest Investments	19 Jul 2005

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

Undisclosed

SV Health Investors, Advent Venture Partners

24 May 2009

Venture Round

Undisclosed

01 Jan 2009

Venture Round

$9.10M

OrbiMed, First Eagle Investment Management +4

28 Jun 2007

Venture Round

Undisclosed

Essex Woodlands Healthcare Partners

07 Mar 2007

Venture Round

$18.60M

OrbiMed, Merlin Biomed +8

07 Nov 2006

Venture Round

$12.53M

Perceptive Advisors, Highbridge Capital Management +3

13 Dec 2005

Venture Round

$13.97M

OrbiMed, ProQuest Investments

19 Jul 2005

FAQ About EUSA Pharma

Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in the Recordati group

EUSA Pharma was founded in 2006.

EUSA Pharma is headquartered in Hemel Hempstead, United Kingdom.

EUSA Pharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Rare Diseases, Cancer Treatment, Specialty Pharmaceuticals and Adult and Pediatric Care. Its customers include Patients with Common Diseases, Patients with Rare Diseases and Investors.

EUSA Pharma has a B2B business model. Its revenue comes from Product Sales, Licensing and Service Fee.

EUSA Pharma has approximately 107 employees.

EUSA Pharma has completed 7 funding rounds, raising a total of $54.20M. The latest funding stage is Venture round.

EUSA Pharma offers: Development of Medicines, Commercialization of Medicines, Healthcare Research, Pharmaceutical Manufacturing.

Top alternatives and competitors to EUSA Pharma include Biodexa Pharmaceuticals PLC, Biogen, Centurion İlaç, VEM PHARMACEUTICALS, KAMADA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

EUSA Pharma and Biodexa Pharmaceuticals PLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About EUSA Pharma

Services & Products

Target Customers

Funding Rounds & Investors (7)

EUSA Pharma Alternatives & Competitors

FAQ About EUSA Pharma